

## Product datasheet for TL313483V

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### **DHFR Human shRNA Lentiviral Particle (Locus ID 1719)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** DHFR Human shRNA Lentiviral Particle (Locus ID 1719)

**Locus ID:** 1719

**Synonyms:** DHFRP1; DYR

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** DHFR - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 000791, NM 001290354, NM 001290357, NR 110936, NM 000791.1, NM 000791.2,

NM 000791.3, NM 001290357.1, NM 001290354.1, BC000192, BC003584, BC009634,

BC070280, BC071996, NM 001290354.2, NM 001290357.2, NM 000791.4

UniProt ID: P00374

**Summary:** Dihydrofolate reductase converts dihydrofolate into tetrahydrofolate, a methyl group shuttle

required for the de novo synthesis of purines, thymidylic acid, and certain amino acids. While the functional dihydrofolate reductase gene has been mapped to chromosome 5, multiple

intronless processed pseudogenes or dihydrofolate reductase-like genes have been identified on separate chromosomes. Dihydrofolate reductase deficiency has been linked to

megaloblastic anemia. Several transcript variants encoding different isoforms have been

found for this gene. [provided by RefSeq, Mar 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact  $\underline{\mathsf{techsupport}} \underline{\mathsf{oorigene.com}}.$ 

If you need a special design or shRNA sequence, please utilize our custom shRNA service.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).